Free Newsletter
Indian court spurns Novartis on patent challenge
Thrilling AIDS activists and frustrating the drug company, an Indian court rejected Novartis' challenge to its drug patent laws. Novartis claims the decision will discourage innovation. Indian law doesn't allow new patents on drugs that have simply been modified, rather than newly developed. That throws a big wrench into drug makers' strategy for combating cheaper generics: namely, using a few pips and tweaks to turn old, once-profitable meds into new, patent-protected ones. The ruling will help protect India's burgeoning generics industry from Big Pharma competition and, say patient advocates, keeps inexpensive remedies coming to populations that couldn't afford them otherwise.
- here's the report from the International Herald Tribune
Related Articles:
Novartis patent challenge spurs protests in India. Report
Generic competition slashes prices. Report
India's biotech future is bright. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: